What was left out of Sandrock’s Aduhelm letter

In an open letter to the Alzheimer’s disease community, Biogen’s Head of R&D Alfred Sandrock aimed to dispel what he called “extensive misinformation and misunderstanding” about Aduhelm circulating among patients, caregivers and physicians. The letter’s simplified messages could resonate with its audience, or the information and nuance left out of the discussion could exacerbate confusion.

The first issue Sandrock took on is the idea that all previously studied anti-amyloid antibodies cleared amyloid from the brain but failed to slow disease progression, suggesting the class is not effective. ...